These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 232936)

  • 21. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore-forming gram-positive baccilli.
    Chow AW; Patten V; Guze LB
    J Infect Dis; 1975 Feb; 131(2):182-5. PubMed ID: 163867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
    Thadepalli H; Chuah SK; Gollapudi S
    Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of antimicrobial resistance and resistance transfer in anaerobic bacteria.
    Tally FP; Malamy MH
    Scand J Infect Dis Suppl; 1982; 35():37-44. PubMed ID: 6300995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
    Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
    Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology and antimicrobial resistance of B. fragilis group organisms isolated from clinical specimen and human intestinal microbiota.
    de Carvalho CB; Moreira JL; Ferreira MC
    Rev Inst Med Trop Sao Paulo; 1996; 38(5):329-35. PubMed ID: 9293074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of the liver and biliary tract to anaerobic infection in extrahepatic biliary tract obstruction. III. Possible synergistic effect between anaerobic and aerobic bacteria. An experimental study in rabbits.
    Lykkegaard Nielsen M; Asnaes S; Justesen T
    Scand J Gastroenterol; 1976; 11(3):263-72. PubMed ID: 775613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between metronidazole metabolism and bactericidal activity.
    Chrystal EJ; Koch RL; McLafferty MA; Goldman P
    Antimicrob Agents Chemother; 1980 Oct; 18(4):566-73. PubMed ID: 6255861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in-vitro activity of metronidazole against Enterobacteriaceae alone and in mixed cultures with Bacteroides fragilis.
    Moran FJ; Perez C; Hurtado C; Blanco MT; Prieto J
    J Antimicrob Chemother; 1987 Nov; 20(5):657-61. PubMed ID: 3429370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaerobic infections in childhood.
    Brook I
    Am Fam Physician; 1986 Oct; 34(4):130-6. PubMed ID: 2876620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
    Nord CE; Olsson-Liljequist B
    Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clindamycin, metronidazole, and chloramphenicol.
    Kasten MJ
    Mayo Clin Proc; 1999 Aug; 74(8):825-33. PubMed ID: 10473362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of a model of intraabdominal sepsis for studies of the pathogenicity of Bacteroides fragilis.
    Onderdonk AB; Shapiro ME; Finberg RW; Zaleznik DF; Kasper DL
    Rev Infect Dis; 1984; 6 Suppl 1():S91-5. PubMed ID: 6372042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.
    Aldridge KE
    Am J Surg; 1995 May; 169(5A Suppl):2S-7S. PubMed ID: 7755163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats.
    Nord CE; Edlund C; Lahnborg G
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():59-63. PubMed ID: 2872197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of metronidazole, chloramphenicol, clindamycin and penicillin G on growth and neuraminidase activity of Bacteroides fragilis.
    Ferreira MC; Domingues RM; de Uzeda M
    J Antimicrob Chemother; 1989 Aug; 24(2):157-64. PubMed ID: 2793640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model.
    Rotstein OD; Kao J; Houston K
    J Med Microbiol; 1989 Aug; 29(4):269-76. PubMed ID: 2668529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.
    Onderdonk AB
    Am J Surg; 1998 Dec; 176(6A Suppl):39S-45S. PubMed ID: 9935256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.